Hyperfine (HYPR) Cash from Financing Activities (2021 - 2026)
Hyperfine (HYPR) reported Cash from Financing Activities of $14.5 million for Q1 2026, up 159.51% on a YoY basis from $5.6 million in Q1 2025, and down 24.87% quarter-over-quarter from $19.3 million in Q4 2025.
Hyperfine (HYPR) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Hyperfine has reported Cash from Financing Activities for 6 years, with the latest figure at $14.5 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 159.51% year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $36.4 million (up 456.16% YoY), and the FY2025 full-year result was $27.5 million, up 2598.92% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $14.5 million, down from $19.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $19.3 million in Q4 2025, with the low at $5000.0 in Q4 2022.
- Historically, Cash from Financing Activities has averaged $3.1 million across 5 years, with a median of $58500.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.0% — and 2025, when it jumped 35607.41%.
- Hyperfine's Cash from Financing Activities stood at $5000.0 in 2022, then surged by 460.0% to $28000.0 in 2023, then surged by 92.86% to $54000.0 in 2024, then jumped by 35607.41% to $19.3 million in 2025, then dropped by 24.87% to $14.5 million in 2026.
- The last three Cash from Financing Activities figures came in at $14.5 million (Q1 2026), $19.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Hyperfine | 155.82 Mn | 114.55 Mn | 1.98 Mn | 14.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.49 Mn |
| Mar 31, 2026 | 14.49 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 474,000.00 |
| Jun 30, 2025 | 474,000.00 |
| Mar 31, 2025 | 5.58 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 54,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Dec 31, 2023 | 28,000.00 |
| Dec 31, 2023 | 28,000.00 |